US-based biopharmaceutical company Clovis Oncology raises $75m through follow-on offering
The deal follows Clovis’ initial public offering (IPO) on November 15, offering 10 million shares at $13.00 per share, raising a total of $130m.
Clovis is focused on acquiring, developing and commercialising anti-cancer agents in the US, Europe and additional international markets.
Founded in 2009 a year after its management team sold Pharmion for $2.9bn to peer Celgene, Clovis closed a $146m series A in May of that year funded by investment group Abingworth and venture capital (VC) investors Domain Associates, New Enterprise Associates (NEA), Versant Ventures, Aberdare Ventures, Frazier Healthcare Ventures and ProQuest Investments. The series A round was followed by a $20m investment by drug company Pfizer, in June, as part of a licensing deal for anti-tumour treatments.